Member Info for 54retiresoon

I recommend going to RNS in news & events on London stock exchange website a few minutes after 7 to see all the 7 am releases.

Tissue Regenix announces new collaboration with a leading global healthcare company and further distribution agreements
Deals underscore demand for Company's product portfolio
Leeds, 11 May 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group" or "Company"), a leading regenerative medicine company, is pleased to announce that it has entered a new strategic collaboration for white label manufacturing with a leading top 10 global healthcare company bringing to market a newly developed product line.
The manufacturing agreement follows collaboration between the R&D teams of both companies to develop a new product using one of the Group's proprietary technology platforms to address orthopaedic soft tissue repairs. Processing for the product has begun, and initial orders have been received. Over the next two years, it is expected that the product will make a material contribution to the Group's top line revenue growth. This new product line is complimentary to the other soft tissue products processed at the San Antonio facility, and due to operational efficiencies implemented, it is not expected that there will be any impact on the current processing levels of other product lines.
In addition, during Q1 2020, the Group signed further distribution agreements with a number of selected partners to expand the market penetration of its AmnioWorks®, Matrix OI®, and DentalFix® brands in areas such as ocular, spinal, and dental, where there is increasing demand for the differentiated product lines. To minimise capacity constraints at the San Antonio facility, the recent distribution agreements target products and therapeutic areas which are complementary to current processing activities and diversify the Group's sales portfolio.
Gareth Jones, Interim CEO, Tissue Regenix Group plc, commented:
"I am delighted to confirm the launch of our first product from our latest strategic collaboration with a leading healthcare company. This exciting opportunity will allow Tissue Regenix to drive its commercial strategy forward and ensure the continued growth of the business with minimal impact to our existing strategic partners and customer base. Securing these important partnerships and distribution agreements underscore the differentiation of, and increasing market demand for, our products; providing further validation of the exciting growth potential for the business once we have completed the planned expansion of our processing capacity."

I am not sure that is the American way and there noses will have been put out by not having exclusivity to the test.

I would be surprised if a Big Pharma company wanted to take a small stake in an up and coming biotech company. If they are convinced about the tech and the potential then they will want to takeover before any competitors realise.

I don't bed & Isa due to being out of the
Market. My method is to buy in my ISA
first & then sell from my taxed account.

Why the extra 3.75m raised. Simply the big shareholders kicked up a fuss about their dilution. Need them on board to get the 2m passed at AGM in my opinion

RNS said Avacta retained all rights to reagants so if Cytiva test is approved could partner with other big pharma to produce similar tests in Europe and Asia to meet demand.

Novacyt was at 6p before Covid-19 after 66x increase it is valued at £270 million. Avacta was valued at c£30 million before the first RNS about their test. If their test is approved then given the likely billions of tests required you can see the potential increase in share value. However, it is the longer term impact on the company of such a breakthrough that is most exciting. It proves the value of their unique technology and will lead to an increase in joint ventures with big pharma and probably provides all the funding they will need to bring their cancer treatments through trials. There is an If but to have such a big pharma company putting their weight behind the test and their previous work on Zika suggests to me that is an if with a good probability of becoming reality.

Amrik Basran Avacta's Chief Scientific Officer is scheduled to open Day 2 of the above conference in September in Boston with a presentation on Affimer Therapeutics: A Versatile Antibody Mimetic Platform for the Generation of Bispecific Immunotherapies. Most of the top Pharma companies represented at the Conference so great exposure for Affimers.

Sinden888 I disagree I think the SP could end the day back around 1p on the back of this. Risk has definitely reduced, not eliminated I grant you but definitely reduced.

Good news essentially £1/2 MILLION free money from US Govt, cash runway extended into July. 18% Yr on Yr increase in revenues Q1. Talks with investors continue.

Opens at 35 now 45

Two more at 30 then 31

The RNS we've been waiting for. Guess the end of day close - for me c. 40p

Far more likely that market makers have picked up a load of shares from a big sell which will appear only when they have been bought. If demand outstrips supply then price rises.

1/2 million shares bought at 0.65 at 16:45

Two extensions worth waiting to see what prices any late trades are at as two extensions suggest volatility.

Now. 68 trade

Latest trade at. 64

Latest trade at 0.6p